


these amendments. Applicants also amended the claim term "the unusual number of platelets" to recite that the subject in question had a "reduced platelet count." The specification states that this invention is designed to treat hemopathy (any disease of the blood) that results in thrombocytopenia. (Specification, page 22, lines 1-7). Thrombocytopenia is medically defined as a reduction in the number of platelets in the blood, and can be caused by a variety of conditions or problems. No new matter has been added by way of these amendments.

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: August 9, 2002

By: 

Mark J. Feldstein  
Reg. No. 46,693

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)